Dominick Angiolillo

  • Dominick J. Angiolillo, MD, PhD
    Dominick J. Angiolillo, MD, PhD

    Division of Cardiology, University of Florida College of Medicine


    Dr. Dominick Angiolillo graduated summa cum laude from the Catholic University of the Sacred Heart Medical School in Rome, Italy, where he completed training in Medicine and Cardiology. He subsequently pursued training in Interventional Cardiology at the Complutense University of Madrid in Spain. Ultimately, Dr. Angiolillo received his Ph.D. in cellular and molecular cardiology. After completing his training in the most prestigious academic centers in Europe, Dr. Angiolillo joined the University of Florida College of Medicine – Jacksonville in 2004. Currently, Dr. Angiolillo is a professor of medicine with tenure status. He is also the director of Cardiovascular Research, program director of the Interventional Cardiology Fellowship Program and a staff cardiologist and interventional cardiologist with the University of Florida Health System. Dr. Angiolillo is board certified by the American Board of Internal Medicine in internal medicine, cardiovascular disease and interventional cardiology.

    Much of Dr. Angiolillo’s professional career has been devoted to cardiovascular research in the field of interventional cardiology and acute coronary syndrome. His largest national and international recognition has been for his pivotal contributions in the field of thrombosis. In particular, Dr. Angiolillo has performed seminal studies on platelet function and modulation of antiplatelet drug response, including genetic studies, for which he has received numerous national and international academic recognitions. Amongst these he has received the 2013 Outstanding Achievement Award from the European Society of Cardiology and was most recently named to Thomson Reuters’ 2014 list of The World’s Most Influential Scientific Minds. He has also been a key investigator in the clinical development of numerous novel antithrombotic agents, working along slide with drug regulating agencies in the United States (FDA) and Europe (EMA), towards approval of these drugs and product labeling updates. His success in obtaining extramural funding has allowed to develop one of the most active clinical research centers in the United States as well as one of the leading centers for thrombosis research in the world.